Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds to that pain and inconvenience. But new developments from companies such as Novo Nordisk A|S (NYSE: NVO), Rockley Photonics Holdings Ltd (NYSE: RKLY), Movano Inc (NASDAQ: MOVE) and Know Labs Inc . (OTCQB: KNWN) are reportedly on the verge of changing the game for those dealing with diabetes. The U.S. Food and Drug Administration (FDA) recently approved Rybelsus, also known as oral semaglutide, which controls blood sugar in Type 2 diabetes patients. Novo, which developed Rybelsus, has not revealed what the pill will cost. Still, the company claims it is committed to working with health insurance providers and pharmacy benefit managers to increase patient access. Novo is not yet done and is awaiting more guidance from the FDA on a second Rybelsus indication — reducing the risk of cardiovascular issues in Type 2 diabetes patients.